Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.

Anthony BuissonMaria NachuryThomas GuilmoteauRomain AltweggXavier TretonMathurin FumeryMelanie SerreroEloïse LeclercLudovic CailloBruno PereiraAurélien Amiot Guillaume Bouguen

Published in: Alimentary pharmacology & therapeutics (2022)

Tofacitinib and vedolizumab are effective in UC after failure of anti-TNF agents. However, tofacitinib seems more effective, especially in severe disease and primary failure to biologics.

Keyphrases

ulcerative colitis
rheumatoid arthritis
randomized controlled trial
systematic review
early onset
drug induced
clinical evaluation